pirenzepine has been researched along with Disease Exacerbation in 15 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the safety and efficacy of the relatively selective M(1)-antagonist, pirenzepine ophthalmic gel (gel), in slowing the progression of myopia in school-aged children." | 9.11 | One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. ( Chua, WH; Crockett, RS; Lam, DS; Shu-Ping, DF; Tan, DT, 2005) |
| "To evaluate the safety and efficacy of the relatively selective M(1)-antagonist, pirenzepine ophthalmic gel (gel), in slowing the progression of myopia in school-aged children." | 5.11 | One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. ( Chua, WH; Crockett, RS; Lam, DS; Shu-Ping, DF; Tan, DT, 2005) |
| "Atropine eye drops and pirenzepine eye gel are highly effective for controlling myopia progression in children." | 4.98 | Epidemiology of myopia and prevention of myopia progression in children in East Asia: a review. ( Chen, LJ; Lee, SM; Mak, CY; Yam, JC; Young, AL, 2018) |
| "The most likely effective treatment to slow myopia progression thus far is anti-muscarinic topical medication." | 2.47 | Interventions to slow progression of myopia in children. ( Cotter, SA; Lindsley, K; Mutti, DO; Twelker, JD; Vedula, SS; Walline, JJ, 2011) |
| "represents a breakthrough in the treatment of myopia and clearly indicates that we will be able in the near future to slow down or even block the progression of this refractive anomaly." | 2.43 | [Fundamentals of modern treatment of myopia]. ( Czepita, D, 2005) |
| "Nearly all participants who treat myopia used at least one form of effective treatment, regardless of location (98%, p=0." | 1.56 | Practice patterns to decrease myopia progression differ among paediatric ophthalmologists around the world. ( Farzavandi, SK; Gomez-de-Liaño, R; Leshno, A; Mezer, E; Sprunger, DT; Wygnanski-Jaffe, T, 2020) |
| "Myopia is a huge public health problem worldwide, reaching the highest incidence in Asia." | 1.39 | Muscarinic cholinergic receptor (M2) plays a crucial role in the development of myopia in mice. ( Barathi, VA; Beuerman, RW; Goh, LK; Kwan, JL; Seet, LF; Tan, QS; Vithana, EN; Weon, SR, 2013) |
| "Myopia is the most common human eye disorder." | 1.37 | An evidence-based update on myopia and interventions to retard its progression. ( Leo, SW; Young, TL, 2011) |
| "A 45-year-old man with well-controlled type 2 diabetes mellitus experienced an abrupt worsening of his diabetes after 3 years of olanzapine therapy His hemoglobin A1c (HbA1c) level rose from a baseline of 5." | 1.31 | Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. ( Bechara, CI; Goldman-Levine, JD, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Leshno, A | 1 |
| Farzavandi, SK | 1 |
| Gomez-de-Liaño, R | 1 |
| Sprunger, DT | 1 |
| Wygnanski-Jaffe, T | 1 |
| Mezer, E | 1 |
| Mak, CY | 1 |
| Yam, JC | 1 |
| Chen, LJ | 1 |
| Lee, SM | 1 |
| Young, AL | 1 |
| Barathi, VA | 1 |
| Kwan, JL | 1 |
| Tan, QS | 1 |
| Weon, SR | 1 |
| Seet, LF | 1 |
| Goh, LK | 1 |
| Vithana, EN | 1 |
| Beuerman, RW | 1 |
| Leo, SW | 1 |
| Young, TL | 1 |
| Walline, JJ | 1 |
| Lindsley, K | 1 |
| Vedula, SS | 1 |
| Cotter, SA | 1 |
| Mutti, DO | 1 |
| Twelker, JD | 1 |
| Saw, SM | 1 |
| Gazzard, G | 1 |
| Au Eong, KG | 1 |
| Tan, DT | 2 |
| Baker, RW | 1 |
| Milton, DR | 1 |
| Stauffer, VL | 1 |
| Gelenberg, A | 1 |
| Tohen, M | 1 |
| Bartlett, JD | 1 |
| Niemann, K | 1 |
| Houde, B | 1 |
| Allred, T | 1 |
| Edmondson, MJ | 1 |
| Crockett, RS | 2 |
| Béliard, S | 1 |
| Valero, R | 1 |
| Vialettes, B | 1 |
| Lam, DS | 1 |
| Chua, WH | 1 |
| Shu-Ping, DF | 1 |
| Czepita, D | 1 |
| Volavka, J | 1 |
| Citrome, L | 1 |
| Bullimore, MA | 1 |
| Bechara, CI | 1 |
| Goldman-Levine, JD | 1 |
| Parker, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vice-president, Nurse, Principal Investigator[NCT02903628] | 1,517 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| Orthokeratology for High Myopia (OHM) Study[NCT03881358] | 66 participants (Anticipated) | Interventional | 2018-08-04 | Recruiting | |||
| Myopia Progression in Children Wearing Near Center and Distance Center Multifocals - a Randomized Controlled Clinical Trial[NCT03519490] | 0 participants (Actual) | Interventional | 2018-06-01 | Withdrawn (stopped due to Lack of interest and support) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for pirenzepine and Disease Exacerbation
| Article | Year |
|---|---|
Epidemiology of myopia and prevention of myopia progression in children in East Asia: a review.
Topics: Administration, Ophthalmic; Asia, Eastern; Atropine; Child; Contact Lenses; Disease Progression; Eye | 2018 |
Interventions to slow progression of myopia in children.
Topics: Atropine; Child; Contact Lenses; Cyclopentolate; Disease Progression; Eyeglasses; Humans; Muscarinic | 2011 |
Interventions to slow progression of myopia in children.
Topics: Atropine; Child; Contact Lenses; Cyclopentolate; Disease Progression; Eyeglasses; Humans; Muscarinic | 2011 |
Interventions to slow progression of myopia in children.
Topics: Atropine; Child; Contact Lenses; Cyclopentolate; Disease Progression; Eyeglasses; Humans; Muscarinic | 2011 |
Interventions to slow progression of myopia in children.
Topics: Atropine; Child; Contact Lenses; Cyclopentolate; Disease Progression; Eyeglasses; Humans; Muscarinic | 2011 |
Myopia: attempts to arrest progression.
Topics: Accommodation, Ocular; Adolescent; Adult; Atropine; Biofeedback, Psychology; Child; Contact Lenses; | 2002 |
[Fundamentals of modern treatment of myopia].
Topics: Administration, Topical; Animals; Child; Disease Progression; Gels; Humans; Myopia; Pirenzepine | 2005 |
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Disease Progressio | 1999 |
What can be done for my child?
Topics: Child; Contact Lenses; Disease Progression; Humans; Muscarinic Antagonists; Myopia; Ophthalmic Solut | 2000 |
4 trials available for pirenzepine and Disease Exacerbation
| Article | Year |
|---|---|
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Disease Progression; Double-Blind Me | 2003 |
A tolerability study of pirenzepine ophthalmic gel in myopic children.
Topics: Child; Disease Progression; Female; Gels; Humans; Male; Muscarinic Antagonists; Myopia; Ophthalmic S | 2003 |
One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia.
Topics: Adolescent; Child; Disease Progression; Double-Blind Method; Female; Gels; Humans; Male; Muscarinic | 2005 |
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.
Topics: Adult; Affect; Aged; Antipsychotic Agents; Anxiety; Benzodiazepines; Depressive Disorder; Disease Pr | 2002 |
5 other studies available for pirenzepine and Disease Exacerbation
| Article | Year |
|---|---|
Practice patterns to decrease myopia progression differ among paediatric ophthalmologists around the world.
Topics: Atropine; Behavior Therapy; Child, Preschool; Disease Progression; Eyeglasses; Female; Global Health | 2020 |
Muscarinic cholinergic receptor (M2) plays a crucial role in the development of myopia in mice.
Topics: Adult; Aged; Alkaloids; Animals; Cell Proliferation; Collagen; Disease Progression; Extracellular Ma | 2013 |
An evidence-based update on myopia and interventions to retard its progression.
Topics: Animals; Atropine; Disease Models, Animal; Disease Progression; Female; Humans; Male; Muscarinic Ant | 2011 |
Atypical neuroleptics and diabetes.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Disease Pro | 2003 |
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.
Topics: Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hyperglycemi | 2001 |